Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: SGLT2i Nov 13 | 2019Empa T1DM FDA Adcom Overwhelmingly Negative (2-14); Is SGLTi in T1DM Approvable in the US?Purchase Blast
$599
Posted in: Bolus Insulin Nov 12 | 2019Oramed Oral Insulin (ORMD-0801) Ph2b T2DM Results UnclearPurchase Blast
$599
Posted in: SGLT2i Nov 12 | 2019BI/Lilly Initiate Jardiance Acute HF Study (EMPULSE)Purchase Blast
$599
Posted in: SGLT2i Nov 08 | 2019Empa T1DM Adcom Could Be Easier Than Sota, But Still Difficult; Briefing Documents AnalysisPurchase Blast
$599
Posted in: Insulin Delivery Nov 08 | 2019Patient Dies on t:slim X2 with Basal IQ; Tandem Denies InvolvementPurchase Blast
$599
Posted in: SGLT2i Nov 07 | 2019Lexicon Disputes Sota CRL with FDA; Lexicon and Xeris Q3 '19 Earnings Updates; Dexcom +30% TodayPurchase Blast
$599
Posted in: Glucose Monitoring Nov 06 | 2019Dexcom and Livongo Q3 '19 Earnings UpdatesPurchase Blast
$599
Posted in: Glucose Monitoring Nov 05 | 2019WaveForm CGM Receives CE Mark; Senseonics Sensor RecallPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery Nov 05 | 2019Mylan and BD Q3 '19 Earnings UpdatesPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Nov 04 | 2019Tandem Q3 '19 Earnings UpdatePurchase Blast
$599
Posted in: SGLT2i Nov 04 | 2019Janssen Partners for Invokana DKD Promotion; BI/Lilly Update Alliance TermsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Nov 04 | 2019Novo Q3 '19 London Earnings UpdatePurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other Nov 01 | 2019Novo has a PCSK9i; Novo Q3 '19 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist Oct 31 | 2019Sanofi Discontinues Tri-Agonist; Sanofi Q3 '19 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other Oct 30 | 2019Thoughts on Verily/Onduo Novel Diabetes Life Insurance ProgramPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
